Bank of New York Mellon Corp lifted its holdings in shares of Calithera Biosciences, Inc. (NASDAQ:CALA) by 230.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,102 shares of the biotechnology company’s stock after purchasing an additional 75,414 shares during the quarter. Bank of New York Mellon Corp owned 0.31% of Calithera Biosciences worth $1,605,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in CALA. Nationwide Fund Advisors acquired a new stake in shares of Calithera Biosciences during the first quarter worth about $131,000. Raymond James Financial Services Advisors Inc. acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $117,000. SG Americas Securities LLC acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $211,000. Victory Capital Management Inc. acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $1,168,000. Finally, United Services Automobile Association acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $342,000. 71.21% of the stock is currently owned by institutional investors.
In other news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 16.30% of the company’s stock.
Shares of Calithera Biosciences, Inc. (CALA) traded up 6.49% during midday trading on Friday, reaching $16.40. The company had a trading volume of 338,972 shares. Calithera Biosciences, Inc. has a one year low of $2.20 and a one year high of $20.05. The company has a 50 day moving average of $16.25 and a 200 day moving average of $14.97. The company’s market capitalization is $581.81 million.
Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.14. The firm had revenue of $7.26 million during the quarter, compared to analysts’ expectations of $4.80 million. Analysts predict that Calithera Biosciences, Inc. will post ($0.81) EPS for the current fiscal year.
A number of research analysts have weighed in on CALA shares. BidaskClub upgraded Calithera Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, July 7th. Zacks Investment Research downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, William Blair initiated coverage on Calithera Biosciences in a report on Thursday, October 5th. They issued an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $15.50.
COPYRIGHT VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/10/28/bank-of-new-york-mellon-corp-acquires-75414-shares-of-calithera-biosciences-inc-cala.html.
Calithera Biosciences Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.